• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Marpai Inc. (Amendment)

    5/29/24 4:01:02 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care
    Get the next $MRAI alert in real time by email
    SC 13D/A 1 yaron_13d_5.1224.htm SC 13D/A SC 13D/A

     

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549 SCHEDULE 13D

    (Amendment No. 3)

    Under the Securities Exchange Act of 1934

     

    MARPAI, INC.

     

    (Name of Issuer)

     

    Class A Common Stock, $0.0001 par value (Title of Class of Securities)

     

    571354 109

     

    (CUSIP Number)

     

    Yaron Eitan c/o Marpai, Inc.

    615 Channelside Drive, Suite 207

    Tampa, Florida 33602

    (855) 389-7330

     

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    May 29, 2024

     

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See 240.13d-7(b) for other parties to whom copies are to be sent.

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

     

     

    SCHEDULE 13D

     

    CUSIP No. 571354 109

     

     


     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Yaron Eitan

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a)
    (b)
    x

    3

    SEC USE ONLY

    4

    SOURCE OF FUNDS (See Instructions)

     

    PF

    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

    o

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Dual Citizenship: United States citizen and Israeli citizen

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

    WITH

    7

    SOLE VOTING POWER 785,902(1)

    8

    SHARED VOTING POWER

    0

    9

    SOLE DISPOSITIVE POWER 785,902(1)

    10

    SHARED DISPOSITIVE POWER 0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    785,902(1)

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    5.7%(2)

    14

    TYPE OF REPORTING PERSON (See Instructions)

     

    IN

     

    (1)
    Comprised of (i) 624,454 shares of the Class A common stock, par value $0.0001 per share (the “Common Stock”) of Marpai, Inc. (the “Issuer”) held directly by Yaron Eitan, (ii) 56,948 shares of Common Stock issuable upon the exercise of warrants at an exercise price of $31.60 per share expiring on February 9, 2026 (the “Warrants”), (iii) 42,000 restricted stock units vesting over the next 2 years; and (iii) 62,500 options to purchase 62,500 shares of Common Stock (the “Options”).

     

     

    (2)
    Percentage is calculated based on 11,012,048 shares of Common Stock outstanding as of May 29, 2024.

     

    This Amendment No. 2 to Schedule 13D (this “Schedule 13D/A”) amends and supplements the Schedule 13D initially filed with the Securities and Exchange Commission (the “SEC”) on December 21, 2021, Amendment No. 1 to Schedule 13D filed on November 24, 2023 and Amendment No. 2 to Schedule 13D filed on January 1, 2024 (collectively, the “Schedule 13D”)

     

    Item 3. Source and Amount of Funds or Other Considerations

     


     

     

    On May 10, 2024, the Reporting Person purchased 5,000 shares of Common Stock of the Issuer at a weighted average purchase price of $2.66. The Reporting Person paid such consideration using personal funds.

     

    On May 23, 2024, the Reporting Person granted 60,000 shares of Restricted Stock Units to be vested over the next 3 years.

     

    Item 4. Purpose of Transaction

     

    Yaron Eitan acquired the securities for business investment purposes.

     

    Item 5. Interest in Securities of the Issuer

     

    (a) As of May 29, 2024, Yaron Eitan directly beneficially owned 785,902 shares of the Issuer’s Common Stock which are comprised of 624,454 shares of Common Stock, 56,948 Warrants to purchase 56,948 shares of Common Stock, 42,000 restricted stock units, and 62,500 Options to purchase 62,500 shares of Common Stock.

     

     

    (b) Yaron Eitan has sole voting and dispositive power of 624,454 shares of Common Stock of the Issuer, as of May 29, 2024.

     

    (c)
    Not applicable.

     

    (d)
    Not applicable.

     

    (e)
    Not applicable.

     

     

     

     

     


     

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated : May 29, 2024

     

     

     

    By: /s/ Yaron Eitan

    Yaron Eitan

     

     

     

     

     

     


    Get the next $MRAI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRAI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MRAI
    SEC Filings

    See more
    • SEC Form 10-K filed by Marpai Inc.

      10-K - Marpai, Inc. (0001844392) (Filer)

      3/26/25 7:30:28 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Marpai Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Marpai, Inc. (0001844392) (Filer)

      2/6/25 4:01:26 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Marpai Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

      8-K - Marpai, Inc. (0001844392) (Filer)

      1/6/25 4:15:22 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care

    $MRAI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MARPAI TO HOST WEBCAST ON MAY 15, 2025 TO DISCUSS FIRST QUARTER 2025 FINANCIAL RESULTS

      TAMPA, Fla., May 7, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services. The Company will host a conference call and webcast on Thursday, May 15 at 8:30 a.m. ET to present the Company's operational and financial highlights for Q1 2025. The Company will report its first quarter 2025 results on Wednesday after the market close. Event: Marpai 2025 Q1 Financial Results Conference Call Date: May 15, 2025 Time: 8:30 a.m. Eastern Time Call:    US: 1-646-357-8785 / Toll Free: 1-800-836-8184 Webcast:    https://app.webinar.net/e6RGaxOgz3n Follow us on X.com and LinkedIn You may stream th

      5/7/25 4:03:00 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Marpai, Inc. to Present at the Planet MicroCap Showcase Las Vegas

      The investor conference is in partnership with MicroCapClub on Wednesday, April 23, 2025 & 1x1 Meetings on Thursday, April 24, 2025 TAMPA, Fla., April 15, 2025 /PRNewswire/ -- Marpai, Inc. (OTCQX:MRAI),  a technology platform company, which operates as a national Third-Party Administrator (TPA) through its subsidiaries and offers affordable, intelligent, healthcare solutions to self-funded employer health plans, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025 at 5:30 PM (Local Time -PST). Marpai's CEO, Damien Lamendola and CFO, Steve Johnson will be hosting the presentation and answering ques

      4/15/25 10:49:00 AM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • MARPAI REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

      MARPAI EXHIBITS STRONG, ONGOING FINANCIAL IMPROVEMENT TAMPA, Fla., March 26, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a technology platform company, which operates as a national Third-Party Administrator (TPA) through its subsidiaries and is transforming the $22 billion TPA market by offering affordable, intelligent, healthcare solutions to self-funded employer health plans, today announced the financial results for the fourth quarter and fiscal year 2024. The Company expects to hold a webcast to discuss the results on March 27, 2025. Q4 2024 Financial Highlights: Net revenues were $6.6 million in Q4 2024, a decrease of $0.4 million, or 6.0% lower than Q3 2

      3/26/25 4:15:00 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care

    $MRAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Lamendola Damien was granted 600,000 shares (SEC Form 4)

      4 - Marpai, Inc. (0001844392) (Issuer)

      1/29/25 4:01:10 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • New insider Intelligent Fanatics Capital Management Llc claimed ownership of 3,729,414 shares (SEC Form 3)

      3 - Marpai, Inc. (0001844392) (Issuer)

      1/2/25 9:41:02 AM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • President and COO Powers John Paul was granted 100,000 shares and bought $11,300 worth of shares (10,000 units at $1.13), increasing direct ownership by 73% to 260,000 units (SEC Form 4)

      4 - Marpai, Inc. (0001844392) (Issuer)

      12/9/24 5:15:20 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care

    $MRAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Marpai Inc.

      SC 13D/A - Marpai, Inc. (0001844392) (Subject)

      12/9/24 5:14:07 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Marpai Inc.

      SC 13D/A - Marpai, Inc. (0001844392) (Subject)

      9/4/24 7:55:41 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13D/A filed by Marpai Inc. (Amendment)

      SC 13D/A - Marpai, Inc. (0001844392) (Subject)

      5/29/24 4:01:02 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care

    $MRAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and COO Powers John Paul was granted 100,000 shares and bought $11,300 worth of shares (10,000 units at $1.13), increasing direct ownership by 73% to 260,000 units (SEC Form 4)

      4 - Marpai, Inc. (0001844392) (Issuer)

      12/9/24 5:15:20 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Chief Financial Officer Johnson Steve Andrew was granted 100,000 shares and bought $5,650 worth of shares (5,000 units at $1.13), increasing direct ownership by 29% to 473,061 units (SEC Form 4)

      4 - Marpai, Inc. (0001844392) (Issuer)

      12/9/24 5:14:54 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Director Eitan Yaron was granted 5,000 shares and bought $124,999 worth of shares (110,619 units at $1.13), increasing direct ownership by 17% to 789,073 units (SEC Form 4)

      4 - Marpai, Inc. (0001844392) (Issuer)

      12/9/24 5:14:32 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care

    $MRAI
    Financials

    Live finance-specific insights

    See more
    • MARPAI TO HOST WEBCAST ON MAY 15, 2025 TO DISCUSS FIRST QUARTER 2025 FINANCIAL RESULTS

      TAMPA, Fla., May 7, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services. The Company will host a conference call and webcast on Thursday, May 15 at 8:30 a.m. ET to present the Company's operational and financial highlights for Q1 2025. The Company will report its first quarter 2025 results on Wednesday after the market close. Event: Marpai 2025 Q1 Financial Results Conference Call Date: May 15, 2025 Time: 8:30 a.m. Eastern Time Call:    US: 1-646-357-8785 / Toll Free: 1-800-836-8184 Webcast:    https://app.webinar.net/e6RGaxOgz3n Follow us on X.com and LinkedIn You may stream th

      5/7/25 4:03:00 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • MARPAI TO HOST WEBCAST ON MARCH 27, 2025 TO DISCUSS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

      TAMPA, Fla., March 20, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a technology platform company, operates as a national Third-Party Administrator (TPA) through its subsidiaries. We're transforming the $22 billion TPA market by offering affordable, intelligent, healthcare solutions to self-funded employer health plans. The Company will host a conference call and webcast on Thursday, March 27 at 8:30 a.m. ET to present the Company's operational and financial highlights for 2024. The Company will report its fourth quarter and full year 2024 results on Wednesday after the market close. Event: Marpai 2024 Financial Results Conference Call Date: March 27, 2025 Time

      3/20/25 8:32:00 AM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • MARPAI TO HOST WEBCAST ON NOVEMBER 12, 2024 TO DISCUSS THIRD QUARTER 2024 FINANCIAL RESULTS

      TAMPA, Fla., Nov. 8, 2024 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a technology platform company, operates as a national Third-Party Administrator (TPA) through its subsidiaries. We're transforming the $22 billion TPA market by offering affordable, intelligent, healthcare solutions to self-funded employer health plans. The Company will host a conference call and webcast on Tuesday, November 12 at 8:30 a.m. ET to present the Company's operational and financial highlights for its third quarter 2024. The Company will report its third quarter results on Monday after the market close. Event: Marpai Third Quarter Financial Results Conference Call Date: November 12, 20

      11/8/24 2:45:00 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care

    $MRAI
    Leadership Updates

    Live Leadership Updates

    See more
    • Health In Tech Announces Innovative Collaboration with MARPAI and Vitable DPC to Offer Competitive Quotes in Enhanced Self-Funded Solutions

      STUART, Fla., Jan. 22, 2025 /PRNewswire/ -- Health In Tech, an Insurtech platform company backed by third-party AI technology, is thrilled to announce a new strategic collaboration with Vitable and MARPAI. This collaboration aims to introduce a  competitively priced self-funded health plan to the market. By utilizing the strength of Vitable's Direct Primary Care (DPC), a health plan, and stop-loss coverage, Health In Tech seeks to offer low quotes on their eDIYBS platform, and to set an ambitious standard in affordability and efficiency. Vitable's enhanced primary care plan co

      1/22/25 5:00:00 PM ET
      $HIT
      $MRAI
      Specialty Insurers
      Finance
      Misc Health and Biotechnology Services
      Health Care
    • George Economou Files Definitive Proxy Statement and Sends Letter to Genco Shareholders

      Highlights Urgent Need for An Independent Director Perspective to Address Genco's Persistent Underperformance and Unlock Value for Shareholders Outlines Concerns with Chairman James Dolphin's Outsized Influence in the Genco Boardroom Urges Shareholders to Vote FOR the Election of GK Investor Nominee Robert Pons on the BLUE Universal Proxy Card and WITHHOLD on Genco Board Chairman James Dolphin GK Investor LLC ("GK"), an affiliate of George Economou that is an approximately 5.3% shareholder of Genco Shipping & Trading Limited ("Genco" or the "Company") (NYSE:GNK), today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission in connec

      4/18/24 1:07:00 PM ET
      $GNK
      $INSG
      $MRAI
      $SEAC
      Marine Transportation
      Consumer Discretionary
      Telecommunications Equipment
      Telecommunications
    • MARPAI HIRES JOHN POWERS AS PRESIDENT

      Accomplished Industry Veteran with Proven Track Record of Successful High Growth Operations to support Marpai's vision of Affordable, Intelligent, Healthcare NEW YORK, Jan. 12, 2024 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (NASDAQ:MRAI), an independent national Third-Party Administration company transforming the $22 billion TPA market supporting self-funded employer health plans, today announced the appointment of John Powers as the Company's President. Powers is an accomplished healthcare benefits executive with over 30 years' experience. Powers was previously CEO of Homestead Smart Health Plans. Powers brings deep operations knowledge and an extensive industry network devel

      1/12/24 8:30:00 AM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care